Human Herpes Virus-6 Encephalitis Following Autologous Blood and Marrow Transplant

Human herpesvirus-6 (HHV-6) is a highly prevalent virus that establishes lifelong latency in human hosts. Symptomatic HHV-6 reactivation rarely occurs in immunocompetent individuals and is best described in immunosuppressed patients such as recipients of bone marrow transplants (BMT). In that setting, HHV-6 reactivation has been associated with fever, rash, pneumonitis, encephalitis, and delayed engraftment. While these complications are well documented in allogeneic transplant, the clinical impact of such reactivation is not well known in autologous BMT. We described a case of HHV-6-associated encephalitis in a previously heavily treated patient with multiple myeloma (MM) following a second autologous BMT, and discuss the need for clinicians to be aware of the potential clinical impact of HHV-6 following autologous BMT in the era of immunomodulatory agents.

[1]  G. Salles,et al.  Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients. , 2019, The Journal of infection.

[2]  P. Schaefer,et al.  Case 5-2018: A 63-Year-Old Man with Confusion after Stem-Cell Transplantation. , 2018, The New England journal of medicine.

[3]  Shara N. Pantry,et al.  Latency, Integration, and Reactivation of Human Herpesvirus-6 , 2017, Viruses.

[4]  M. Nojima,et al.  Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay , 2017, Journal of medical virology.

[5]  T. Onaka,et al.  Herpes zoster duplex bilateralis in bortezomib-based chemotherapy , 2016, Blood research.

[6]  Ji‐Won Kim,et al.  Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  E. Shpall,et al.  Characterizing human herpes virus 6 following hematopoietic stem cell transplantation , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[8]  H. Agut,et al.  Laboratory and Clinical Aspects of Human Herpesvirus 6 Infections , 2015, Clinical Microbiology Reviews.

[9]  H. Agut,et al.  Classification of HHV-6A and HHV-6B as distinct viruses , 2014, Archives of Virology.

[10]  S. Kako,et al.  Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  N. Lavi,et al.  New Rising Infection: Human Herpesvirus 6 Is Frequent in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Induction Therapy with Bortezomib , 2012, Bone marrow research.

[12]  P. Armand,et al.  Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  R. Razonable,et al.  Impact of human herpes virus 6 in liver transplantation. , 2010, World journal of hepatology.

[14]  P. Chevallier,et al.  Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source , 2010, Bone Marrow Transplantation.

[15]  A. Verma,et al.  Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.

[16]  S. Pauls,et al.  Challenging complications of treatment – human herpes virus 6 encephalitis and pneumonitis in a patient undergoing autologous stem cell transplantation for relapsed Hodgkin's disease: a case report , 2009, Virology Journal.

[17]  D. Baarle,et al.  Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  R. Yamazaki,et al.  Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  A. Ballestrero,et al.  Proteasome inhibitor‐induced apoptosis in human monocyte‐derived dendritic cells , 2006, European journal of immunology.

[20]  M. Boeckh,et al.  Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  W. Hiddemann,et al.  Impact of human herpesvirus‐6 after haematopoietic stem cell transplantation , 2005, British journal of haematology.

[22]  K. Horibe,et al.  Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. , 2002, The Journal of infectious diseases.

[23]  P. Galieni,et al.  Long-term follow-up of human herpes virus 6 infection in autologous bone marrow transplant recipients. , 2001, Haematologica.

[24]  P. Galieni,et al.  Human herpesvirus 6 infection in autologous bone marrow transplant recipients: A prospective study , 2000, Journal of medical virology.

[25]  F. Wang.  Human herpesvirus 6 infection after allogeneic stem cell transplantation , 1999 .

[26]  P. Pellett,et al.  Human herpesvirus 6: infection and disease following autologous and allogeneic bone marrow transplantation. , 1996, Blood.

[27]  W. Siegert,et al.  Herpesvirus type 6 in patients undergoing bone marrow transplantation: serologic features and detection by polymerase chain reaction. , 1994, Blood.

[28]  E. Tschachler,et al.  In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6) , 1988, The Journal of experimental medicine.

[29]  M. Kaplan,et al.  Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. , 1986, Science.